338 related articles for article (PubMed ID: 27825347)
1. Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients.
Milara J; Cervera A; de Diego A; Sanz C; Juan G; Gavaldà A; Miralpeix M; Morcillo E; Cortijo J
Respir Res; 2016 Nov; 17(1):145. PubMed ID: 27825347
[TBL] [Abstract][Full Text] [Related]
2. In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients.
Milara J; Contreras S; de Diego A; Calbet M; Aparici M; Morcillo E; Miralpeix M; Cortijo J
PLoS One; 2019; 14(1):e0210188. PubMed ID: 30608978
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
Milara J; Lluch J; Almudever P; Freire J; Xiaozhong Q; Cortijo J
J Allergy Clin Immunol; 2014 Aug; 134(2):314-22. PubMed ID: 24636089
[TBL] [Abstract][Full Text] [Related]
4. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Malerba M; Radaeli A; Santini G; Morjaria J; Mores N; Mondino C; Macis G; Montuschi P
Expert Opin Drug Discov; 2018 Jun; 13(6):563-577. PubMed ID: 29616842
[TBL] [Abstract][Full Text] [Related]
5. Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP.
Lambers C; Costa L; Ying Q; Zhong J; Lardinois D; Dekan G; Schuller E; Roth M
Pharmacol Res; 2015 Dec; 102():310-8. PubMed ID: 26546746
[TBL] [Abstract][Full Text] [Related]
6. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
Blasi F; Canonica GW; Miravitlles M
Respir Res; 2017 Jan; 18(1):19. PubMed ID: 28100244
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
8. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
Maltais F; Milot J
Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of granulocyte migration by tiotropium bromide.
Vacca G; Randerath WJ; Gillissen A
Respir Res; 2011 Feb; 12(1):24. PubMed ID: 21352583
[TBL] [Abstract][Full Text] [Related]
10. β₂ long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD.
Profita M; Bonanno A; Montalbano AM; Albano GD; Riccobono L; Siena L; Ferraro M; Casarosa P; Pieper MP; Gjomarkaj M
Biochim Biophys Acta; 2012 Jul; 1822(7):1079-89. PubMed ID: 22440430
[TBL] [Abstract][Full Text] [Related]
11. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
Joos GF
Expert Opin Investig Drugs; 2010 Feb; 19(2):257-64. PubMed ID: 20047505
[TBL] [Abstract][Full Text] [Related]
12. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.
Cazzola M; Calzetta L; Ora J; Puxeddu E; Rogliani P; Matera MG
Respir Med; 2015 Oct; 109(10):1305-11. PubMed ID: 26303336
[TBL] [Abstract][Full Text] [Related]
13. Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo.
Kunz LI; van't Wout EF; van Schadewijk A; Postma DS; Kerstjens HA; Sterk PJ; Hiemstra PS
Respir Res; 2015 Dec; 16():154. PubMed ID: 26696093
[TBL] [Abstract][Full Text] [Related]
14. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
[TBL] [Abstract][Full Text] [Related]
15. Effects of aclidinium bromide in a cigarette smoke-exposed Guinea pig model of chronic obstructive pulmonary disease.
Domínguez-Fandos D; Ferrer E; Puig-Pey R; Carreño C; Prats N; Aparici M; Musri MM; Gavaldà A; Peinado VI; Miralpeix M; Barberà JA
Am J Respir Cell Mol Biol; 2014 Feb; 50(2):337-46. PubMed ID: 24032416
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.
Cazzola M; Calzetta L; Page CP; Rogliani P; Facciolo F; Gavaldà A; Matera MG
Eur J Pharmacol; 2014 Dec; 745():135-43. PubMed ID: 25446566
[TBL] [Abstract][Full Text] [Related]
17. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Gupta V; Singh D
Expert Rev Respir Med; 2012 Dec; 6(6):581-8. PubMed ID: 23234445
[TBL] [Abstract][Full Text] [Related]
18. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD.
Montuschi P; Macagno F; Valente S; Fuso L
Curr Med Chem; 2013; 20(12):1464-76. PubMed ID: 22963553
[TBL] [Abstract][Full Text] [Related]
19. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Rogliani P; Matera MG
Expert Opin Pharmacother; 2013 Apr; 14(6):775-81. PubMed ID: 23472632
[TBL] [Abstract][Full Text] [Related]
20. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease.
Milara J; Díaz-Platas L; Contreras S; Ribera P; Roger I; Ballester B; Montero P; Cogolludo Á; Morcillo E; Cortijo J
Respir Res; 2018 Nov; 19(1):226. PubMed ID: 30458870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
